Connection

Haruhito Sugiyama to Bevacizumab

Back to Details
This is a "connection" page, showing publications Haruhito Sugiyama has written about Bevacizumab.
Haruhito Sugiyama
Connection Strength
0.148
Bevacizumab
  1. A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation. Chin Clin Oncol. 2016 Dec; 5(6):77.
    View in: PubMed
    Score: 0.148
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.